BioSpace News Archive

Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“ PDC ”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that Theralase ® ’s Phase Ib Non-Muscle Invasive Bladder Cancer (“ NMIBC ”) clinical study (“ Study ”.

OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Kevin S. Litwiler, Ph.D., as Senior Vice President of DMPK and Clinical Pharmacology.

Wilmington, Delaware, United States: According to the report, the global elderly and disabled assistive devices market was valued at US$ 20.7 Bn in 2020 and is projected to expand at a CAGR of 5.3% from 2021 to 2028 to reach US$ 31.6 Bn in 2028.

Fact.MR, a Market Research and Competitive Intelligence Provider - As per industry analysis on vancomycin by Fact.MR, a market research and competitive intelligence provider, the global market is predicted to expand at a CAGR of 5.8% over the forecast period and reach US$ 465.1 Million by 2027.

Wilmington, Delaware, United States: The global super-resolution microscopes market is expected to witness moderate growth during the forecast period between 2021 and 2031.

Wilmington, Delaware, United States: The global positron emission tomography market is expected to witness slow growth during the forecast period between 2021 and 2031.

Wilmington, Delaware, United States: Natural language processing or NLP generally refers to the interaction between human and computer that analyzes, processes, and produces computational linguistics all based on a human language.

The Cystic Fibrosis Foundation announced its investment of $6 million in Carbon Biosciences to support the company‘s preclinical research into an innovative gene therapy approach for cystic fibrosis.

Iktos, a company specialized in Artificial Intelligence for new drug design, announced a research collaboration with Zealand Pharma A/S, a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design.

Carbon Biosciences, a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, announced a $38 million Series A financing led by Agent Capital.